Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Completed · Phase 2

Conditions studied: Chronic Myelogenous Leukemia

In brief

To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia chronic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

Key facts

Study ID

NCT00042016

Run by

Astex Pharmaceuticals, Inc.

People needed

40

Starts

2002-07-01

Last updated by the study team

2009-10-14

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Medical Center — Duarte, California, United States
• Scripps Clinic — Escondido, California, United States
• USC/Norris Cancer Center — Los Angeles, California, United States
• Metro-Minnesota CCOP — Saint Louis Park, Minnesota, United States
• New York Medical College — Valhalla, New York, United States
• Liberty Hematology/Oncology — Columbia, South Carolina, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Princess Margaret Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.